PMC:2948432 / 30303-30752 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/2948432","sourcedb":"PMC","sourceid":"2948432","source_url":"https://www.ncbi.nlm.nih.gov/pmc/2948432","text":"We have examined the role of BRAF and NRAS mutations and reduced gene dosage at 9p in melanoma relapse. The study was carried out using formalin-fixed paraffin-embedded (FFPE) tumors because of the difficulties in accessing cryopreserved primary tumors; melanomas are generally too small to allow cryopreservation. In the study, 65% of tumors sampled yielded enough DNA for MLPA screening and 61% were successfully sequenced for BRAF/NRAS mutations.","tracks":[]}